- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Sanofi's U.S. derm unit for sale
French pharmaceutical firm Sanofi-Aventis is looking to sell its U.S. dermatology business, Bloomberg.com reports.
Paris - French pharmaceutical firm Sanofi-Aventis is looking to sell its U.S. dermatology business, Bloomberg.com reports.
The sale price could be as much as $444 million, according to Bloomberg.com. Initial bids were submitted in early April.
Bloomberg.com quotes Sanofi-Aventis CEO Chris Viehbacher as saying, “We are busy reviewing proposals from various groups. We are probably about midway through that process.”
The company reportedly wants to focus on treatments for diabetes, cancer and atrial fibrillation. Paris-based Sanofi’s dermatology products include the dermal filler Sculptra Aesthetic (poly-L-lactic acid).
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
